Quick-Med Technologies, Inc. Senior Scientist Gregory S. Schultz Profiled in TIME Magazine

Schultz' Contribution Critical to the Development of Antimicrobial Technology
Designed to Prevent Dangerous Infections

Gainesville, Florida, March 16, 2006 - Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) ("Quick-Med Technologies" or "QMT") announced today that its Vice President of Clinical Research, Gregory S. Schultz, Ph.D., was profiled in the March 20, 2006 "Annual Issue" of TIME magazine featuring "Innovators - Epidemiology". The article entitled "Forging the Future: Microbe-Busting Bandages" profiles Dr. Schultz and his work in advancing NIMBUST, QMT's proprietary technology for medical devices and value-added consumer applications. NIMBUS is a technology for permanently bonding chemically active molecules to materials such as cotton, cotton blends, paper, or polyurethane to create advanced wound dressings, fabrics or other medical and consumer products.

In the article, Dr. Schultz stated that Quick-Med Technologies' bandages may help reduce the risk of infection as well as minimize outbreaks of drug-resistant staph infections. Unlike other antibacterial products, NIMBUS-based dressings are designed to promote healing while preventing bacteria from developing resistance. Drug resistant bacteria, such as VRE (Vancomycin-Resistant Enterococcus) and MRSA (Methicillin-Resistant Staphylococcus aureus) are a growing concern in healthcare facilities where risks of prolonged illness and fatality due to so-called "Super Bugs" have risen sharply. Quick-Med Technologies is pursuing ongoing research and regulatory approvals for its medical devices or related products.

"Because of the vast number of bacteria that we come into contact with every day, there is a significant need for products that can help reduce the number of infections that are caused by these contacts" stated Dr. Schultz. "On behalf of my colleagues at QMT who have greatly contributed to the advancement of the NIMBUS technology, I am honored to be named an Innovator by TIME magazine."

In another application of the NIMBUS technology, the article further elaborated that "one of the hottest applications" of the Company's technology is fighting burns from sulfur mustard, or mustard gas. Mustard gas quickly penetrates the skin, eyes and airways causing blisters, eye irritation, blindness and death in higher concentrations. At present, there are no specialized wound dressings designed for mustard gas exposure. Decontamination using neutralizing agents is the only treatment for such vesicant exposures. In November 2005, Quick-Med Technologies announced in that the U.S. Army Small Business Innovative Research (SBIR) program had competitively awarded a Phase I contract to the Company to design a prototype wound dressing using advancements in the NIMBUS technology to speed the healing of wounds from chemical blister agents.

According to Dr. Schultz, "Many wound-healing dressings require frequent changes, thereby inflicting added burden on the medical logistical system. Similarly, additions of various growth factors, antiproteases, and nutritive substances have been shown to be beneficial when added to the wound bed. There is a need for a product, which can be used to treat chemical casualties that combine the features of several of these products. The current effort would use existing technology or products to develop a single, new dressing with all of these features. This is expected to be technically challenging and will require innovative and creative approaches to meet the technical goals."

In a related and previously announced product initiative, QMT is working to develop a post-injury drug to treat mustard gas exposure, in addition to today's announced wound dressing designed to promote healing of chemical injuries.

About Gregory S. Schultz, Ph. D. Dr. Schultz joined Quick-Med Technologies, Inc. in 2000 as Vice President of Clinical Research, and Director. From 1999 through 2001, Dr. Schultz served as the president of the Wound Healing Society and has worked as a consultant for 12 major biotechnology companies. In 1989, he was appointed professor of Obstetrics/Gynecology and director of the Institute for Wound Research in the College of Medicine at the University of Florida at Gainesville, Florida. He has published over 200 research articles and book chapters that have been cited over 4,000 times. Dr. Schultz has been continuously funded by major grants from the National Institutes of Health and supported by grants from the U.S. Army grant on treatment of burns with growth factors. Dr. Schultz earned a doctorate in biochemistry from Oklahoma State University, and postdoctoral fellowship in cell biology at Yale University in Connecticut.

About Quick-Med Technologies, Inc.
Quick-Med Technologies is a life sciences company focused in developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company¹s two core products under development are (1) MultiStat™, a family of advanced compounds shown to be effective in broad-based skin therapy applications, and (2) NIMBUS™, a family of advanced polymers that can be used in a wide range of applications from advanced wound care to wood preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies¹ website: www.quickmedtech.com or email: info@quickmed-technologies.com

For additional further information, please contact QMT:

David S. Lerner -- President
Phone : (561) 750-4202
Email: dlerner@quickmed-technologies.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.